BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Ixmyelocel-T: SPA received

Aastrom received an SPA from FDA for the planned double-blind, placebo-controlled, U.S. Phase III REVIVE-CLI trial to evaluate ixmyelocel-T in up to 594...

Read the full 94 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >